scholarly journals Intestinal Alkaline Phosphatase Deficiency Is Associated with Ischemic Heart Disease

2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Jagannath Malo ◽  
Md. Jahangir Alam ◽  
Munjareen Shahnaz ◽  
Kanakaraju Kaliannan ◽  
Gopal Chandra ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Regression Analysis ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Strong Association ◽  
Multiple Logistic Regression Analysis ◽  
Ischemic Heart ◽  
Intestinal Alkaline Phosphatase ◽  
The Metabolic Syndrome ◽  
High Level

Background. We have previously shown that the deficiency of the gut enzyme intestinal alkaline phosphatase (IAP) is associated with type 2 diabetes mellitus (T2DM) in humans, and mice deficient in IAP develop the metabolic syndrome, a precipitant of T2DM and ischemic heart disease (IHD). We hypothesized that IAP deficiency might also be associated with IHD in humans. We aimed to determine the correlation between the IAP level and IHD in humans. Methods and Results. The IHD patients were recruited from the National Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh, and the control healthy participants were recruited from a suburban community of Dhaka. We determined the IAP level in the stools of 292 IHD patients (187 males, 105 females) and 331 healthy control people (84 males, 247 females). We found that compared to controls, IHD patients have approx. 30% less IAP (mean±SEM: 63.7±3.5 vs. 44.9±2.1 U/g stool, respectively; p<0.000001), which indicates that IAP deficiency is associated with IHD, and a high level of IAP is probably protective against IHD in humans. The adjusted generalized linear model (GLM) of regression analysis predicted a strong association of IAP with IHD (p=0.0035). Multiple logistic regression analysis showed an independent inverse relationship between the IAP level and the IHD status (odds ratio, OR=0.993 with 95% CI 0.987-0.998; p<0.01). Conclusions. IAP deficiency is associated with IHD, and a high level of IAP might be protective against IHD.

Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease

2006 ◽  
Vol 186 (2) ◽  
pp. 367-373 ◽  
Author(s):  
Derrick Heng ◽  
Stefan Ma ◽  
Jeannette J.M. Lee ◽  
Bee Choo Tai ◽  
Koon Hou Mak ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
At Risk ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Ischemic Heart ◽  
The Metabolic Syndrome

scholarly journals Plasma levels of pentosidine in diabetic patients: an advanced glycation end product.

1998 ◽  
Vol 9 (9) ◽  
pp. 1681-1688
Author(s):  
S Sugiyama ◽  
T Miyata ◽  
Y Ueda ◽  
H Tanaka ◽  
K Maeda ◽  
...  
Keyword(s):  
Renal Function ◽  
Regression Analysis ◽  
Heart Disease ◽  
Serum Creatinine ◽  
Ischemic Heart Disease ◽  
Multiple Regression Analysis ◽  
Multiple Regression ◽  
Ischemic Heart ◽  
Diabetic Patients ◽  
Advanced Glycation

Nonenzymatic reactions between glucose and proteins yield advanced glycation end products (AGE) such as pentosidine. AGE accumulate in diabetic patients, alter the structure and function of tissue proteins, stimulate cellular response, and have thus been implicated in diabetic tissue damage. The present study was undertaken to assess the factors determining plasma total pentosidine level in diabetic patients and the possible relation between plasma pentosidine level and diabetic complications. In diabetic patients, including patients with renal failure, plasma pentosidine levels, assessed by HPLC assay, were correlated with serum creatinine (P < 0.0001). In patients with normal renal function, pentosidine levels were correlated with blood glucose control (hemoglobin Alc: P = 0.0028; fructoselysine: P = 0.0133), serum creatinine (P = 0.029), patient age (P = 0.0416), duration of diabetes (P = 0.0431), and total cholesterol (P = 0.0056) and LDL-cholesterol (P = 0.0208). Multiple regression analysis revealed an independent influence of hemoglobin Alc and serum creatinine on pentosidine levels (r2 = 0.216, P = 0.0026). Pentosidine levels were higher in patients with than in those without hypertension (P = 0.043) or ischemic heart diseases (P = 0.0061). No such differences were observed between patients with and without albuminuria or retinopathy. Multiple regression analysis revealed an independent influence of plasma pentosidine on the presence of hypertension (r2 = 0.129, P = 0.0382) and of plasma pentosidine and HDL-cholesterol on the presence of ischemic heart disease (r2 = 0.326, P = 0.0012). The present study demonstrated that plasma pentosidine level was significantly influenced by the quality of glycemic control and renal function. Pentosidine level was also correlated with hypertension and ischemic heart disease, and might be taken as a biomarker of diabetic cardiovascular risk.

scholarly journals Comparison of four definitions of the metabolic syndrome and odds of ischemic heart disease in the Lithuanian urban population

2011 ◽  
Vol 57 (3) ◽  
pp. 543-550 ◽  
Author(s):  
Dalia Ieva Luksiene ◽  
Migle Baceviciene ◽  
Abdonas Tamosiunas ◽  
Regina Reklaitiene ◽  
Ricardas Radisauskas
Keyword(s):  
Metabolic Syndrome ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Urban Population ◽  
Ischemic Heart ◽  
The Metabolic Syndrome

scholarly journals SAT-541 Difference in Aldosterone Dependency Between Cardiovascular Diseases and Renal Impairments in Patients with Primary Aldosteronism

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Masakatsu Sone ◽  
Youichi Ohno ◽  
Akiyuki Kawashima ◽  
Nobuya Inagaki ◽  
Mitsuhide Naruse ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Regression Analysis ◽  
Heart Disease ◽  
Renal Impairment ◽  
Ischemic Heart Disease ◽  
Logistic Regression Analysis ◽  
Primary Aldosteronism ◽  
Odds Ratio ◽  
Plasma Aldosterone ◽  
Ischemic Heart

Abstract BACKGROUND: There have been several clinical studies examining the factors associated with cardiovascular disease (CVD) and renal impairment in patients with primary aldosteronism (PA); however, their results have left it unclear as to whether they are affected by the plasma aldosterone concentration (PAC) itself. Method: This is a retrospective cross-sectional study. We assessed the PA database established by the multicenter JPAS (Japan Primary Aldosteronism Study) and compared the prevalences of CVD (stroke, ischemic heart disease, and heart failure) and renal impairment (proteinuria and lowered eGFR) among patients with PA and those with essential hypertension (EHT). We also performed logistic regression analysis to determine which parameters significantly increased the odds ratio for these complications. Results: The prevalence of CVD was significantly higher among 2814 patients with PA than among matched patients with EHT. The prevalence of proteinuria was also significantly higher among PA than EHT patients, whereas there was no significant difference in the prevalence of lowered eGFR. Multivariable logistic regression analysis showed that the PAC significantly increases the adjusted odds ratios for proteinuria and lowered eGFR independent of other known risk factors. By contrast, the PAC was not linearly related to the adjusted odds ratio for CVD. Conclusion: Plasma aldosterone levels are closely associated with renal impairment in patients with PA. This is contrast to our finding that the PAC was not, itself, linearly associated with CVDs, such as stroke or ischemic heart disease. The mechanism underlying the kidney damage in patients with PA may thus differ from that affecting the cardiovascular system.

Sign in / Sign up

Export Citation Format

Share Document